Asset 1

Target Expression and Prevalence Screening

Make better clinical trial decisions and adopt clinical trial ready assays faster.

Biomarkers provide insight into the interactions between a cancer indication and the therapeutic at a molecular level. These insights empower decision making, and can be the difference between success and failure in the clinical setting.

Discovery’s experts help researchers adopt clinical trial ready immunohistochemistry (IHC) assays early in the drug development process as a low-cost, high-impact strategy to help accelerate clinical trials and improve clinical outcomes.

Advantages of Discovery’s Target Expression and Prevalence Screening Services


“We have been working with Discovery Life Sciences in Kassel, previously Targos GmbH, for many years on clinical validation of tissue biomarkers. This partnership is based on strong scientific focus and an open and honest relationship which led to the approvals of many companion diagnostics assays for Agilent and our pharma partners. We always appreciate the consistent high-quality services and the mutual trust we've developed over the years across our various internal functions such as R&D, Marketing, CDx, and Clinical Trials. DLS has also established a fantastic Biomarker Academy training program that, in my opinion, has become a valuable cornerstone in the global pathology community.”

We worked with 3 histology vendors to develop IHC assay for novel tumor antigen using commercially available IHC antibodies.  Only the DLS team was able to deliver robust and specific assay with staining characteristics that were suitable for our range-finding studies.  Leveraging their in-house biorepository, DLS was able to deliver a data package with scoring intensities for this antigen for 178 patient samples across 13 cancer indications. This information has been extremely valuable in understanding the clinical opportunity that targeting this antigen would provide.

In the past five of years, we have entrusted Discovery Life Sciences with the development and validation of a FISH assay for a novel biomarker (MAF-Test) predicting relapse in breast cancer and the response to specific drugs in adjuvant setting. DLS's expertise in assay development and target validation helps create a reliable scoring scheme accelerating identification of patients eligible for further treatment. Furthermore, DLS's experience in molecular pathology and consultative service approach always exceeded our expectations

Contact Us Today

Quick Links


Development and Clinical
Trial Solutions